U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

MedGen UID:
1624768
•Concept ID:
C4527336
•
Neoplastic Process

Definition

The reemergence of primary cutaneous diffuse large B-cell lymphoma, leg type after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Professional guidelines

PubMed

Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Zehnder M, Amarov B, Abrunhosa-Branquinho AN, Maiwald-Urosevic M, Mühleisen B, Saulite I, Anzengruber F, Imhof L, Navarini AA, Cozzio A, Dummer R, Dimitriou F, Guenova E
Dermatology 2022;238(5):967-976. Epub 2022 Feb 14 doi: 10.1159/000522053. PMID: 35158362
Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
Fabbri A, Cencini E, Alterini R, Rubegni P, Rigacci L, Delfino C, Puccini B, Fimiani M, Bosi A, Bocchia M, Pimpinelli N; Gruppo Italiano Linfomi Cutanei (GILC)
Eur J Haematol 2014 Aug;93(2):129-36. Epub 2014 Apr 4 doi: 10.1111/ejh.12315. PMID: 24635751
Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience.
Hamilton SN, Wai ES, Tan K, Alexander C, Gascoyne RD, Connors JM
Int J Radiat Oncol Biol Phys 2013 Nov 15;87(4):719-25. Epub 2013 Aug 31 doi: 10.1016/j.ijrobp.2013.07.019. PMID: 24001373

Recent clinical studies

Etiology

Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
Primary cutaneous B-cell lymphoma: A single-center 5-year experience.
Jacob LA, Asati V, Lakshmaiah KC, Govind BK, Lokanatha D, Babu SM, Lokesh KN, Rudresh AH, Rajeev LK, Mulchandani NJ, Anand A, Koppaka D, Mysore SN
Indian J Cancer 2018 Apr-Jun;55(2):134-137. doi: 10.4103/ijc.IJC_418_17. PMID: 30604723
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article
Cutaneous lymphomas: an update. Part 2: B-cell lymphomas and related conditions.
Kempf W, Kazakov DV, Mitteldorf C
Am J Dermatopathol 2014 Mar;36(3):197-208; quiz 209-10. doi: 10.1097/DAD.0b013e318289b20e. PMID: 24658377
Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg-type and other: an update on morphology and treatment.
Paulli M, Lucioni M, Maffi A, Croci GA, Nicola M, Berti E
G Ital Dermatol Venereol 2012 Dec;147(6):589-602. PMID: 23149705

Diagnosis

Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
Primary cutaneous B-cell lymphoma: A single-center 5-year experience.
Jacob LA, Asati V, Lakshmaiah KC, Govind BK, Lokanatha D, Babu SM, Lokesh KN, Rudresh AH, Rajeev LK, Mulchandani NJ, Anand A, Koppaka D, Mysore SN
Indian J Cancer 2018 Apr-Jun;55(2):134-137. doi: 10.4103/ijc.IJC_418_17. PMID: 30604723
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article
Cutaneous lymphomas: an update. Part 2: B-cell lymphomas and related conditions.
Kempf W, Kazakov DV, Mitteldorf C
Am J Dermatopathol 2014 Mar;36(3):197-208; quiz 209-10. doi: 10.1097/DAD.0b013e318289b20e. PMID: 24658377
Primary cutaneous B-cell lymphomas.
Kempf W, Denisjuk N, Kerl K, Cozzio A, Sander C
J Dtsch Dermatol Ges 2012 Jan;10(1):12-22; quiz 23. doi: 10.1111/j.1610-0387.2011.07852.x. PMID: 22212142

Therapy

Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Zehnder M, Amarov B, Abrunhosa-Branquinho AN, Maiwald-Urosevic M, Mühleisen B, Saulite I, Anzengruber F, Imhof L, Navarini AA, Cozzio A, Dummer R, Dimitriou F, Guenova E
Dermatology 2022;238(5):967-976. Epub 2022 Feb 14 doi: 10.1159/000522053. PMID: 35158362
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.
Beylot-Barry M, Mermin D, Maillard A, Bouabdallah R, Bonnet N, Duval-Modeste AB, Mortier L, Ingen-Housz-Oro S, Ram-Wolff C, Barete S, Dalle S, Maubec E, Quereux G, Templier I, Bagot M, Grange F, Joly P, Vergier B, Vially PJ, Gros A, Pham-Ledard A, Frison E, Merlio JP
J Invest Dermatol 2018 Sep;138(9):1982-1989. Epub 2018 Mar 27 doi: 10.1016/j.jid.2018.03.1516. PMID: 29596904
Primary cutaneous diffuse large B cell lymphoma-other successfully treated by the combination of R-CHOP chemotherapy and surgery: A case report and review of literature.
Jia J, Li W, Zheng Y
Medicine (Baltimore) 2017 Feb;96(8):e6161. doi: 10.1097/MD.0000000000006161. PMID: 28225499Free PMC Article
Primary cutaneous B-cell lymphomas.
Kempf W, Denisjuk N, Kerl K, Cozzio A, Sander C
J Dtsch Dermatol Ges 2012 Jan;10(1):12-22; quiz 23. doi: 10.1111/j.1610-0387.2011.07852.x. PMID: 22212142

Prognosis

Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article
Cutaneous lymphomas: an update. Part 2: B-cell lymphomas and related conditions.
Kempf W, Kazakov DV, Mitteldorf C
Am J Dermatopathol 2014 Mar;36(3):197-208; quiz 209-10. doi: 10.1097/DAD.0b013e318289b20e. PMID: 24658377
Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg-type and other: an update on morphology and treatment.
Paulli M, Lucioni M, Maffi A, Croci GA, Nicola M, Berti E
G Ital Dermatol Venereol 2012 Dec;147(6):589-602. PMID: 23149705
Primary cutaneous B-cell lymphomas.
Kempf W, Denisjuk N, Kerl K, Cozzio A, Sander C
J Dtsch Dermatol Ges 2012 Jan;10(1):12-22; quiz 23. doi: 10.1111/j.1610-0387.2011.07852.x. PMID: 22212142

Clinical prediction guides

Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J
Hematol Oncol 2021 Dec;39(5):658-663. Epub 2021 Aug 28 doi: 10.1002/hon.2919. PMID: 34453851
Primary cutaneous B-cell lymphoma: A single-center 5-year experience.
Jacob LA, Asati V, Lakshmaiah KC, Govind BK, Lokanatha D, Babu SM, Lokesh KN, Rudresh AH, Rajeev LK, Mulchandani NJ, Anand A, Koppaka D, Mysore SN
Indian J Cancer 2018 Apr-Jun;55(2):134-137. doi: 10.4103/ijc.IJC_418_17. PMID: 30604723
Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA, Olszewski AJ
Curr Treat Options Oncol 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. PMID: 29931605Free PMC Article
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA, Louissaint A Jr, Wenzel A, Yang J, Martinez-Escala ME, Moy AP, Morgan EA, Paxton CN, Hong B, Andersen EF, Guitart J, Behdad A, Cerroni L, Weinstock DM, Choi J
J Invest Dermatol 2018 Nov;138(11):2365-2376. Epub 2018 May 30 doi: 10.1016/j.jid.2018.04.038. PMID: 29857068Free PMC Article
Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines.
Pedretti S, Urpis M, Leali C, Borghetti P, Baushi L, Sala R, Tucci A, Greco D, Pasinetti N, Triggiani L, Rossi G, Calzavara-Pinton P, Magrini SM, Buglione M
Tumori 2018 Oct;104(5):394-400. Epub 2018 May 8 doi: 10.5301/tj.5000606. PMID: 28218382

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...